<p>Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]</p>
نویسندگان
چکیده
منابع مشابه
Parkinson’s disease: carbidopa, nausea, and dyskinesia
When l-dopa use began in the early 1960s for the treatment of Parkinson's disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically been attributed to l-dopa. The ...
متن کاملEffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
OBJECTIVE The purpose of this study was to assess the effect of levodopa-carbidopa intestinal gel (carbidopa-levodopa enteral suspension) in advanced Parkinson's disease patients with troublesome dyskinesia. METHODS Post hoc analyses of patient data from a 12-week, randomized, double-blind study and a 54-week open-label study were performed. Efficacy was assessed in the subgroup of patients d...
متن کاملThe Parkinson’s disease death rate: carbidopa and vitamin B6
The only indication for carbidopa and benserazide is the management of L-3,4-dihydroxyphenylalanine (L-dopa)-induced nausea. Both drugs irreversibly bind to and permanently deactivate pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, and PLP-dependent enzymes. PLP is required for the function of over 300 enzymes and proteins. Virtually every major system in the body is impacted direc...
متن کاملDyskinesia in Parkinson's Disease Therapy
L-DOPA is still regarded as the standard pharmacotherapy for the treatment of the motor symptoms of Parkinson's disease (PD). However, the efficacy of this drug is limited by the emergence of dystonic and choreic involuntary movements, generally referred to as dyskinesia. Current interventions to treat dyskinesia are mainly based on continuous delivery of L-DOPA, administration of glutamatergic...
متن کاملDiabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study
Background and Objective: Dyskinesia is a debilitating complication of Parkinsonchr('39')s disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation. Materials and Methods: In this case-control study, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Pharmacology: Advances and Applications
سال: 2020
ISSN: 1179-1438
DOI: 10.2147/cpaa.s240233